摘要:
The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
摘要:
The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
摘要翻译:本发明涉及与TL1A结合的抗体或其片段。 更具体地,本发明涉及结合TL1A的抗体或其片段,其包含包含SEQ ID NO:51的氨基酸序列的重链CDR1和/或包含SEQ ID NO:51的氨基酸序列的重链CDR2 :52,和/或包含SEQ ID NO:53的氨基酸序列的重链CDR3; 和/或包含包含SEQ ID NO:54的氨基酸序列的轻链CDR1和/或包含SEQ ID NO:55的氨基酸序列的轻链CDR2和/或包含氨基酸序列的轻链CDR3 的SEQ ID NO:56。
摘要:
The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
摘要:
The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
摘要翻译:本发明涉及与人类OX40结合的拮抗剂抗体或其片段。 更具体地说,本发明涉及与人OX40结合的拮抗性抗体或其片段,其包含包含SEQ ID NO:1的氨基酸序列的重链CDR1和/或包含SEQ ID NO:1的氨基酸序列的重链CDR2 ID NO:2,和/或包含SEQ ID NO:3的氨基酸序列的重链CDR3; 和/或包含包含SEQ ID NO:4的氨基酸序列的轻链CDR1和/或包含SEQ ID NO:5的氨基酸序列的轻链CDR2和/或包含氨基酸序列的轻链CDR3 的SEQ ID NO:6。
摘要:
The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.
摘要:
The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.
摘要翻译:本发明涉及与CCR6结合的抗体或其片段。 更具体地,本发明涉及结合CCR6的抗体或其片段,所述CCR6包含含有SEQ ID NO:31的氨基酸序列的重链CDR1和/或含有SEQ ID NO:31的氨基酸序列的重链CDR2 :32,SEQ ID NO:190,SEQ ID NO:239,SEQ ID NO:240,SEQ ID NO:241,SEQ ID NO:242,SEQ ID NO:254或SEQ ID NO:255和/或重链 包含SEQ ID NO:33的氨基酸序列的CDR3; 和/或包含含有SEQ ID NO:34,SEQ ID NO:191,SEQ ID NO:244,SEQ ID NO:245,SEQ ID NO:246或SEQ ID NO:256的氨基酸序列的轻链CDR1, 和/或包含SEQ ID NO:35,SEQ ID NO:247,SEQ ID NO:248或SEQ ID NO:257的氨基酸序列的轻链CDR2和/或包含SEQ ID NO:35的氨基酸序列的轻链CDR3 ID NO:36或SEQ ID NO:192或SEQ ID NO:193。